We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -1.64 | -1.01% | 161.00 | 163.6923 | 161.14 | 162.73 | 5,178,877 | 01:00:00 |
From May 2019 to May 2024
By Allison Prang
AbbVie Inc. (ABBV) reported a profit, compared with a loss a year earlier, as its research and development costs fell by billions.
The company's profit was $2.8 billion, compared with a loss of $1.83 billion a year earlier. Earnings were $1.88 a share, compared with a loss of $1.23 a share.
Adjusted earnings were $2.21 a share, up from $1.90 a share. According to FactSet, analysts were expecting $2.19 a share.
Net revenue was $8.7 billion, up 4.8%. Analysts were expecting $8.69 billion.
The company's research and development costs sank to $1.54 billion. In the fourth quarter of 2018, they were $6.5 billion. AbbVie also reported $890 million in other operating income.
At the same time, the company reported $416 million in net other expense, compared with net other income of $393 million a year earlier. AbbVie also had $273 million in income tax expense compared with an income tax benefit of $547 million a year earlier.
Write to Allison Prang at allison.prang@wsj.com
(END) Dow Jones Newswires
February 07, 2020 08:24 ET (13:24 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
